P/E ratio for Organovo (ONVO)
P/E ratio as of July 2025 (TTM): -0.1771
According to Organovo's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.177083. At the end of 2024 the company had a P/E ratio of -2.92.
P/E ratio history for Organovo from 2021 to 2024
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -2.92 | 179.27% |
| 2023 | -1.05 | -57.59% |
| 2022 | -2.47 | 53.09% |
| 2021 | -1.61 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Intuitive Surgical ISRG | 71.6 | -40,530.25% | 🇺🇸 USA |
 United Therapeutics UTHR | 11.2 | -6,452.90% | 🇺🇸 USA |
 3D Systems DDD | -0.8038 | 353.93% | 🇺🇸 USA |
 3M MMM | 19.1 | -10,882.01% | 🇺🇸 USA |
 Stratasys SSYS | -7.23 | 3,984.71% | 🇮🇱 Israel |
 General Electric GE | 41.7 | -23,656.47% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.